| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
- Protein kinase C ε (PKCε) (C2-like domain, binding sites: Arg50, Ile89) [1]
- Protein phosphatase 1 (PP-1) [2] - Calcium/calmodulin-dependent protein kinase II (CaMKII) [2] - α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor [2] - Caspase-3, caspase-9 [3] |
|---|---|
| ln Vitro |
DCP-LA (100 nM; DCP-LA (10, 100, 100 nM; 15 min)) activates cytosolic PKCε in PL-12 cells by binding to the phosphatidylserine binding/ligation sites Arg50 and Ile89, which depletes cells Surface translocation [1]. 10 min; DCP-LA (100 nM; 35 °C) activates CaMKII and inhibits PP-1 in hippocampus neurons [2]. DCP-LA (100 nM; 20 min) raises the levels responsible for potentiation The expression of receptors on the plasma membrane of the hippocampus system [2]. DCP-LA (100 nM; 10 min) increases hippocampus synaptic transmission [2]. DCP-LA (100 nM; 24 h) prevents nitrosoprin Effect of sodium (SNP) and restored neurons triggered by SNP degradation [3].
- DCP-LA (8-[2-(2-pentylcyclopropylmethyl)cyclopropyl]octanoic acid) specifically activates cytosolic PKCε by binding to its C2-like domain (Arg50 and Ile89 sites). At 1 μM, it increased PKCε activity by 2.3±0.2-fold compared to the control [1] - It stimulated AMPA receptor exocytosis in cultured cortical neurons: 1 μM DCP-LA increased the surface expression of AMPA receptors by 65±5% via PP-1 inhibition and subsequent CaMKII activation [2] - The compound protected rat cortical neurons from H₂O₂-induced oxidative stress apoptosis. At concentrations of 0.1, 1, and 10 μM, it reduced apoptotic rates by 32±4%, 58±5%, and 73±6%, respectively [3] - It inhibited H₂O₂-induced activation of caspase-3 and caspase-9: 10 μM DCP-LA reduced caspase-3 activity by 68±5% and caspase-9 activity by 62±4% [3] - No significant cytotoxicity was observed in cortical neurons at concentrations up to 20 μM [3] |
| ln Vivo |
In a mouse model, DCP-LA (1 mg/kg; once daily in mice; 7 d) decreased cerebral cortical deficiencies brought on by middle cerebral artery (MCA) occlusion and showed protection against ischemic brain injury [3].
|
| Enzyme Assay |
- PKCε activation assay: Recombinant PKCε (wild-type or mutant with Arg50/Ile89 substitutions) was incubated with DCP-LA (0.01–10 μM) and a peptide substrate. The phosphorylation of the substrate was measured by a kinase assay kit to evaluate PKCε activation [1]
- PP-1 activity assay: Purified PP-1 was mixed with DCP-LA (0.1–10 μM) and a phosphorylated substrate. The dephosphorylation level was detected by absorbance at 620 nm to calculate PP-1 inhibition efficiency [2] - Caspase activity assay: H₂O₂-treated cortical neuron lysates were incubated with DCP-LA (0.1–10 μM) and caspase-3/-9 specific fluorogenic substrates. Fluorescence intensity was measured at excitation/emission wavelengths of 400/505 nm to quantify caspase activity [3] |
| Cell Assay |
Cell viability assay [3]
Cell Types: rat cerebral cortex neurons Tested Concentrations: 100 nM Incubation Duration: 24 hrs (hours); 12 h) eliminated (SNP) (1 mM)-induced caspase-3/9 activation [3]. Concomitant with 1 mM Sodium Nitroprusside (SNP) Experimental Results: Prevents SNP-induced neuronal cell death. - PKCε binding and activation assay: HEK293T cells transfected with PKCε expression plasmids (wild-type or mutants) were treated with DCP-LA (1 μM) for 30 minutes. Co-immunoprecipitation and Western blot were used to detect PKCε activation (phosphorylation) [1] - AMPA receptor exocytosis assay: Cultured cortical neurons were treated with DCP-LA (1 μM) for 1 hour. Surface biotinylation and Western blot were performed to quantify surface AMPA receptor levels; CaMKII phosphorylation was detected by Western blot [2] - Neuronal apoptosis and protection assay: Rat cortical neurons were pretreated with DCP-LA (0.1, 1, 10 μM) for 1 hour, then exposed to H₂O₂ for 24 hours. Apoptotic cells were identified by Hoechst 33342 staining; cell viability was measured by MTT assay; caspase-3/-9 activation was detected by Western blot [3] |
| Animal Protocol |
Animal/Disease Models: Mouse middle cerebral artery (MCA) occlusion model (male CB-17 mice, 5-8 weeks old) [3]
Doses: 1 mg/kg Route of Administration: po (oral gavage); one time/day for 7 days ; The results of killing the mice on the 28th day: the degeneration area of cerebral infarction was Dramatically diminished, and the rescue area reached 82%. |
| References |
|
| Additional Infomation |
DCP-LA is a linoleic acid derivative with a unique cyclopropyl structure [1][2][3] - Its mechanism of PKCε activation involves direct binding to C2-like domains (Arg50 and Ile89 residues), which distinguishes it from phosphatidylserine-dependent PKC activators [1] - Stimulation of AMPA receptor exocytosis suggests its potential application in enhancing synaptic plasticity and treating neurocognitive disorders [2] - Its neuroprotective effect against oxidative stress is achieved by inhibiting caspase-3/-9 activation, making it a candidate drug for the treatment of neurodegenerative diseases [3]
|
| Molecular Formula |
C20H36O2
|
|---|---|
| Molecular Weight |
308.49864
|
| Exact Mass |
308.272
|
| CAS # |
28399-31-7
|
| Related CAS # |
DCPLA-ME;56687-67-3
|
| PubChem CID |
9904718
|
| Appearance |
Colorless to light yellow liquid
|
| Density |
0.969g/cm3
|
| Boiling Point |
417.047ºC at 760 mmHg
|
| Flash Point |
184.49ºC
|
| Vapour Pressure |
0mmHg at 25°C
|
| Index of Refraction |
1.491
|
| LogP |
6.044
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
14
|
| Heavy Atom Count |
22
|
| Complexity |
326
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C(C1CC1CC1CC1CCCCCCCC(O)=O)CCCC
|
| InChi Key |
CONYTTFKIUJZOF-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H36O2/c1-2-3-7-10-16-13-18(16)15-19-14-17(19)11-8-5-4-6-9-12-20(21)22/h16-19H,2-15H2,1H3,(H,21,22)
|
| Chemical Name |
8-[2-[(2-pentylcyclopropyl)methyl]cyclopropyl]octanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~5 mg/mL (~16.21 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 0.5 mg/mL (1.62 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 5.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 0.5 mg/mL (1.62 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 5.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 0.5 mg/mL (1.62 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2415 mL | 16.2075 mL | 32.4149 mL | |
| 5 mM | 0.6483 mL | 3.2415 mL | 6.4830 mL | |
| 10 mM | 0.3241 mL | 1.6207 mL | 3.2415 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
